Keywords: Takeda, Schizophremia, License, Intra-Cellular, CNS pipeline

Takeda in-licenses schizophrenia drug candidates from Intra-Cellular for up to $750 million

Article | 03 March 2011

Print This

In a second licensing deal this year, Japan’s largest drugmaker Takeda Pharmaceutical (TSE: 4502) has entered into an exclusive ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in